Veradermics (MANE) Free Cash Flow (2025 - 2026)
Veradermics' (MANE) quarterly Free Cash Flow came in at -$21.4 million in Q1 2026, down 60.48% YoY from -$54.1 million in Q1 2025, and down 60.48% on a QoQ basis from -$13.3 million in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) Free Cash Flow (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Free Cash Flow data on file, last reported at -$21.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 60.48% year-over-year to -$21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.7 million (changed N/A YoY) and the FY2025 annual result came in at -$71.6 million, down 202.37% from the prior year.
- Free Cash Flow retreated to -$21.4 million in Q1 2026, from -$13.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.3 million in Q1 2025 to a low of -$21.4 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | -14.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.58 Mn |
| Mar 31, 2026 | -21.37 Mn |
| Jun 30, 2025 | -15.68 Mn |
| Mar 31, 2025 | -13.34 Mn |